Nasus Pharma Ltd (NSRX) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Dilution Analysis

Low Risk

Limited dilution potential

Last updated: March 27, 2026

Risk Assessment Details

Potential Dilution: 11.09% of current shares

Recent Dilution: 0% (2 years)

Historical Dilution Factor: minimal recent dilution

Outstanding Shares

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

NSRX currently has 9.02M outstanding shares. with limited dilution risk as only 1M additional shares (11.1%) are authorized for issuance. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
Mar 27, 2026	POS AM filing: This prospectus relates to the resale of up to 5,390,850 Ordinary Shares by selling shareholders, consisting of shares held by the selling shareholders and shares issuable upon the exercise of warrants.	9M	1M
Mar 25, 2026	20-F filing \| 9.0M shares outstanding	9M	1M
Jul 09, 2025	F-1 filing: Nasus Pharma Ltd. is offering 1,000,000 ordinary shares in a firm commitment initial public offering, with an anticipated price between $10.00 and $12.00, and has applied to list its shares on the NYSE American under the symbol "NSRX".	N/A	1M

Back to NSRX Details